158 related articles for article (PubMed ID: 31885185)
1. Outcomes of cataract surgery in eyes with diabetic macular oedema: Data from the Fight Retinal Blindness! Registry.
Bhandari S; Biechl AC; Nguyen V; Squirrell D; Mehta H; Barthelmes D; Gillies MC
Clin Exp Ophthalmol; 2020 May; 48(4):462-469. PubMed ID: 31885185
[TBL] [Abstract][Full Text] [Related]
2. Changes in real-world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5-year outcomes: Data from the Fight Retinal Blindness! Registry.
Biechl AC; Bhandari S; Nguyen V; Arnold JJ; Young S; Fraser-Bell S; Mehta H; Gillies M; Barthelmes D
Clin Exp Ophthalmol; 2020 Aug; 48(6):802-812. PubMed ID: 32383527
[TBL] [Abstract][Full Text] [Related]
3. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Poor Visual Outcomes of Diabetic Macular Edema: The Fight Retinal Blindness! Project.
Shah J; Nguyen V; Hunt A; Mehta H; Romero-Nuñez B; Zarranz-Ventura J; Viola F; Bougamha W; Barnes R; Barthelmes D; Gillies MC; Fraser-Bell S
Ophthalmol Retina; 2022 Jul; 6(7):540-547. PubMed ID: 35307607
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Squirrell D; Nguyen V; Wang N; Wells JM; Tan T; Barnes R; Barry R; Barthelmes D; Gillies M
Eye (Lond); 2022 Mar; 36(3):594-602. PubMed ID: 33767407
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Patients With Active Diabetic Macular Edema at the Time of Cataract Surgery Managed With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Starr MR; Mahr MA; Smith WM; Iezzi R; Barkmeier AJ; Bakri SJ
Am J Ophthalmol; 2021 Sep; 229():194-199. PubMed ID: 33852907
[TBL] [Abstract][Full Text] [Related]
7. Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Bhandari S; Mehta H; Viola F; Arnold J; Fraser-Bell S; Barthelmes D; Creuzot-Garcher C; Gillies M
Acta Ophthalmol; 2022 May; 100(3):285-294. PubMed ID: 33196150
[TBL] [Abstract][Full Text] [Related]
8. Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion.
Bhandari S; Nguyen V; Hunt A; Gabrielle PH; Viola F; Mehta H; Manning L; Squirrell D; Arnold J; McAllister IL; Barthelmes D; Gillies M
Eye (Lond); 2023 Apr; 37(6):1145-1154. PubMed ID: 35508721
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
10. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month results.
Lim LL; Morrison JL; Constantinou M; Rogers S; Sandhu SS; Wickremasinghe SS; Kawasaki R; Al-Qureshi S
Clin Exp Ophthalmol; 2016 May; 44(4):233-42. PubMed ID: 26871700
[TBL] [Abstract][Full Text] [Related]
11. Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients.
Rennie C; Lotery A; Payne J; Singh M; Ghanchi F
Eye (Lond); 2024 Jan; 38(1):215-223. PubMed ID: 37542174
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project.
Daien V; Nguyen V; Morlet N; Arnold JJ; Essex RW; Young S; Hunyor A; Gillies MC; Barthelmes D;
Am J Ophthalmol; 2018 Jun; 190():50-57. PubMed ID: 29550186
[TBL] [Abstract][Full Text] [Related]
13. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Gabrielle PH; Nguyen V; Daien V; Viola F; Bougamha W; Young S; Romero-Nuñez B; Figueras-Roca M; Zarranz-Ventura J; Barthelmes D; Sararols L; Gillies M; Creuzot-Garcher C
Ophthalmol Ther; 2022 Apr; 11(2):797-810. PubMed ID: 35179714
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results.
Kandasamy R; Constantinou M; Rogers SL; Sandhu SS; Wickremasinghe S; Al-Qureshi S; Lim LL
Br J Ophthalmol; 2019 Dec; 103(12):1753-1758. PubMed ID: 30819688
[TBL] [Abstract][Full Text] [Related]
16. Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema.
Cornish EE; Teo KY; Gillies MC; Lim LL; Nguyen V; Wickremasinghe S; Mehta H; McAllister IL; Fraser-Bell S
Br J Ophthalmol; 2023 Jan; 107(1):79-83. PubMed ID: 34340975
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study.
Busch C; Fraser-Bell S; Zur D; Rodríguez-Valdés PJ; Cebeci Z; Lupidi M; Fung AT; Gabrielle PH; Giancipoli E; Chaikitmongkol V; Okada M; Laíns I; Santos AR; Kunavisarut P; Sala-Puigdollers A; Chhablani J; Ozimek M; Hilely A; Unterlauft JD; Loewenstein A; Iglicki M; Rehak M;
Acta Diabetol; 2019 Jul; 56(7):777-784. PubMed ID: 30903434
[TBL] [Abstract][Full Text] [Related]
18. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes.
Ciulla TA; Pollack JS; Williams DF
Br J Ophthalmol; 2021 Feb; 105(2):216-221. PubMed ID: 32265201
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors for visual outcome after intravitreal drug therapy for chronic diabetic macular oedema].
Guthoff R; Schrader W; Hennemann K; Meigen T; Göbel W
Klin Monbl Augenheilkd; 2011 May; 228(5):468-72. PubMed ID: 20597042
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal dexamethasone versus bevacizumab in Aboriginal and Torres Strait Islander patients with diabetic macular oedema: The OASIS study (a randomised control trial).
Meyer J; Fry C; Turner A; Razavi H
Clin Exp Ophthalmol; 2022 Jul; 50(5):522-533. PubMed ID: 35355382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
